ArticleFrontiers in cardiovascular medicine2025
A rare case report: fulminant myocarditis in neonatal lupus erythematosus.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neonatal lupus erythematosus (NLE) is a rare autoimmune disorder caused by the transplacental passage of maternal autoantibodies, such as anti-Ro/SS-A and anti-La/SS-B. It can affect multiple organ systems, resulting in various symptoms. Fulminant myocarditis, a severe inflammatory heart condition and uncommon complication of NLE, may have a favorable prognosis with timely diagnosis and proper treatment. Case presentation: We present a case of a one-month-old female infant with seizures, hypocalcemia, and a maternal history of Sjögren's syndrome, which are compatible with NLE. Further diagnostic assessments detected anti-nuclear antibodies, anti-SSA, and anti-RO52 antibodies. The infant also exhibited elevated cardiac biomarkers and a reduced left ventricular ejection fraction, pointing to fulminant myocarditis. Treatment with intravenous immunoglobulin and methylprednisolone led to remarkable clinical improvement and normalization of laboratory parameters within one year. Conclusions: This case highlights the rarity of fulminant myocarditis in neonatal NLE and emphasizes the critical role of early diagnosis and timely intervention. It also indicates the potential prognostic value of cardiac biomarkers in such cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.